Live feed07:00:00·1dPRReleasevia QuantisnowKymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease WeekByQuantisnow·Wall Street's wire, on your screen.KYMR· Kymera Therapeutics Inc.Health Care
